Rigel Pharmaceuticals, Inc (RIGL)

Etorro trading 970x250
Rigel Pharmaceuticals, Inc (RIGL) Logo

About Rigel Pharmaceuticals, Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Address: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080

Rigel Pharmaceuticals, Inc News and around…

Latest news about Rigel Pharmaceuticals, Inc (RIGL) common stock and company :

Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America
24 May, 2022 FinancialContent

Knight Therapeutics Inc.(TSX: GUD) (OTC: KHTRF)entered into exclusive license and supply agreementswithRigel ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
03 May, 2022 FinancialContent

Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 43.5% to $0.33 during Tuesday's after-market session. Trading volume ...

Recap: Rigel Pharmaceuticals Q1 Earnings
03 May, 2022 FinancialContent

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to ...

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
03 May, 2022 Yahoo! Finance

Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
03 May, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
03 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm ...

Earnings Scheduled For May 3, 2022
03 May, 2022 FinancialContent

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its ...

Preview: Rigel Pharmaceuticals's Earnings
02 May, 2022 FinancialContent

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors ...

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
26 Apr, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2022 financial results after market close on Tuesday, May 3, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
20 Apr, 2022 Yahoo! Finance

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08 Apr, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported the grant of stock options to purchase an aggregate of 626,000 shares of common stock to 15 newly hired employees. These awards were approved by the Compensation Committee of Rigel's Board of Directors and granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of April 7, 2022, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing R

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022
23 Mar, 2022 FinancialContent

Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, ...

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
08 Mar, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) who had failed at least one prior treatment. The published data demonstrate that fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, rapidly and durably increased hemoglobin (Hgb) levels, with clinically meaningful Hgb responses ob

Looking Into Rigel Pharmaceuticals's Return On Capital Employed
07 Mar, 2022 FinancialContent

Rigel Pharmaceuticals (NASDAQ:RIGL) brought in sales totaling $20.41 million during Q4 according to data provided by Benzinga Pro. ...

Analysts Just Made A Major Revision To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Revenue Forecasts
06 Mar, 2022 Yahoo! Finance

Market forces rained on the parade of Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders today, when the analysts...

68 Biggest Movers From Yesterday
03 Mar, 2022 FinancialContent

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial ...

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Rigel (RIGL) delivered earnings and revenue surprises of 0% and 3.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Rigel Pharmaceuticals Q4 Earnings
01 Mar, 2022 FinancialContent

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors ...

Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
01 Mar, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Earnings Scheduled For March 1, 2022
01 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth ...

Rigel Pharmaceuticals's Earnings Outlook
28 Feb, 2022 FinancialContent

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors ...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
22 Feb, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 25% Undervaluation?
22 Feb, 2022 Yahoo! Finance

Does the February share price for Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) reflect what it's really worth? Today, we...

Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates
11 Feb, 2022 Yahoo! Finance

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Shareholders in Rigel Pharmaceuticals (NASDAQ:RIGL) are in the red if they invested a year ago
17 Jan, 2022 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

Stocks That Hit 52-Week Lows On Friday
14 Jan, 2022 FinancialContent

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical ...

Hedge Funds Are Crazy About Rigel Pharmaceuticals, Inc. (RIGL)
12 Jan, 2022 Yahoo! Finance

In this article we are going to use hedge fund sentiment as a tool and determine whether Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

Rigel to Present at the J.P. Morgan Healthcare Conference
10 Jan, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET on Wednesday, January 12, 2022.

Rigel Pharmaceuticals Provides Business Update
10 Jan, 2022 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary 2021 full-year total revenue, the status of the Phase 3 study in COVID-19, and upcoming catalysts in 2022.

Analysts Forecast 17% Gains Ahead For The Holdings of VHT
07 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $296.36 per unit.

Rigel Pharmaceuticals, Inc (RIGL) is a NASDAQ Common Stock listed in , ,

970x250